Analogues of arginine vasopressin and its agonist and antagonist modified in the N-terminal part of the molecule with l-β-homophenylalanine

: In continuation of our efforts to elucidate the role of positions 2 and 3 in arginine vasopressin (AVP) and its analogues, we designed and synthesized peptides modified in these positions with l‐β‐homophenylalanine (β‐Hph). Two of them had just this single modification, the next two peptides are analogues of the V2 agonist, namely [3‐mercaptopropionic acid (Mpa)1]AVP (dAVP). The last two compounds were designed by substitution of positions 2 or 3 of a potent V1a antagonist, [1‐mercaptocyclohexaneacetic acid (Cpa)1]AVP, with β‐Hph. All the peptides were tested for their pressor and antidiuretic and uterotonic in vitro activities in the rat. All the activities tested have been found to be significantly decreased. Three analogues, i.e. [Mpa1,β‐Hph2]AVP, [Cpa1,β‐Hph2]AVP, [Cpa1,β‐Hph3]AVP, turned out to be uterotonic antagonists with pA2 = 6.3 ± 0.2, 6.3 ± 0.1, 6.0 ± 0.3 respectively. The last one exhibited antipressor properties also (pA2 = 6.4 ± 0.1).